The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.33, sa.1, ss.1-7, 2023 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 33 Sayı: 1
- Basım Tarihi: 2023
- Doi Numarası: 10.4999/uhod.236829
- Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.1-7
- Anahtar Kelimeler: AML, Elderly, Comorbidity, Charlson, Prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and patients older than 65 years have a poor prognosis. Patient-related factors, such as comorbid conditions that affect performance status, and insufficient organ functions, explain why elderly patients have a worse prognosis. The Charlson Comorbidity Index (CCI), is used to predict prognosis according to comorbidities. This retrospective study was conducted on patients diagnosed with AML between 2010 and 2019. Patients >60 years were included. Demographic information, comorbidities, CCI, ECOG ( Eastern Cooperative Oncology Group) score, cytogenetic characteristics, treatment regimens, treatment response, follow-up periods were recorded for all patients. Evaluation was made of a total of 82 patients with a mean age of 71.18 ± 7.67. The median follow-up was 6.7 months. The median number of comorbidities was 1 [0.0-4.0] with the median CCI score of 3 [2.0-6.0]. Median overall survival (OS) was 7.0 months [3.1-10.8] and PFS was 6.8 months [3.6-10.0]. As the median CCI score was 3, patients were divided into two groups as CCI > 3 and CCI ≤ 3. Age, gender, ECOG, cytogenetic risk profile, first-line treatment and CR1 achievement status were all similar in both groups (p > 0.05). Patients with CCI > 3 had significantly shorter OS than patients with CCI ≤ 3 (3.6 months [0.3-29.3] vs 8.6 months [0.2-60.2], p= 0.049). The results of the current study demonstrated that CCI, can be used as a prognostic index in elderly patients with AML independently of other patient and disease-related characteristics.